The Pharma Data

AUGUST 30, 2021

Positive high-level results from the FoCus Phase III trial in Wilson disease showed ALXN1840 met the primary endpoint with a statistically significant improvement in daily mean copper mobilisation from tissues, demonstrating superiority compared with standard-of-care (SoC) treatments. 1 It affects one in 30,000 live births in the US.

Trials 52

Trials Genetics Cardiology Medicine 52

XTalks

AUGUST 4, 2022

Cardiovascular clinical trials need to have a diversity plan because there can be a difference in disease burden when comparing people of different race and ethnicity. The US Food and Drug Administration (FDA) is emphasizing the need for diversity in clinical trials. The Diversity of the US Population.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Clinical Research 52

The Pharma Data

AUGUST 22, 2021

Alexion is discontinuing CHAMPION-ALS, the global Phase III clinical trial of Ultomiris (ravulizumab) in adults with amyotrophic lateral sclerosis (ALS). The IDMC recommended that the trial be discontinued due to lack of efficacy. Data from the trial will be provided to inform ongoing research. CHAMPION-ALS.

Trials 52

Trials Clinical Trials Clinical Trials Cardiology 52

The Pharma Data

JANUARY 20, 2021

Trial designed to investigate the cardioprotective properties of CardiolRx(TM) in patients hospitalized with COVID-19 who have a prior history of, or risk factors for, cardiovascular disease. The DSMC comprises independent experts who will assess the patient safety data, and, if needed, critical efficacy endpoints of the trial.

Trials 52

Trials Cardiology Containment Development 52

ACRP blog

JANUARY 24, 2023

Raising Community Awareness to Optimize Impact Nevada’s first integrated health system was created in June 2021 when an affiliation agreement was signed between Renown Health and the University of Nevada, Reno, School of Medicine. An important step was a review of the state of clinical trial awareness at the time of the affiliation agreement.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 29, 2021

Heerspink, Professor of Clinical Trials and Personalized Medicine and a clinical pharmacologist/trialist at the Department of Clinical Pharmacy and Pharmacology at the University center Groningen, Netherlands, and Co-Chair of the study’s Executive Committee. In July, finerenone was approved under the name Kerendia® by the us (U.S.)

Clinical Development 52

Clinical Development Development Clinical Trials Clinical Trials 52

Velocity Clinical Research

JANUARY 3, 2024

The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. In most cases, the participant of a clinical trial benefits from taking part, which is of great importance, especially in oncological trials. and Europe.

Clinical Trials 52

Clinical Trials Clinical Trials Clinical Research Trials 52

The Pharma Data

OCTOBER 28, 2021

Bayer will present new renal and cardiovascular (CV) analyses from the comprehensive finerenone (Kerendia®) clinical trial program, including the Phase III FIGARO-DKD and FIDELIO-DKD studies, and the prespecified pooled analysis FIDELITY at the American Society of Nephrology (ASN)’s Kidney Week 2021 from 4-7 November.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Branding 52

The Pharma Data

NOVEMBER 8, 2021

In the FIGARO-DKD study, presented at ESC Congress 2021 and published in the New England Journal of Medicine, the prevalence of the first secondary endpoint, a compound of time to order failure, a sustained drop of estimated glomerular filtration rate (eGFR) ? cases in the finerenone arm and 395 (10.8)

Clinical Trials 52

Clinical Trials Clinical Trials Trials HR 52

Delveinsight

DECEMBER 29, 2020

Myovant Sciences have decided to put their forces and efforts together to advance the Prostate cancer market as they announced their partnership deal to develop and market relugolix for prostate cancer and women’s health. . Audentes Therapeutics’ ASPIRO Trial Free to Proceed. Billion Myovant/ Pfizer Deal. mg) in the US and Canada.

Trials 52

Trials Drugs Hormones Radiology 52

Drug Discovery World

OCTOBER 19, 2022

Following the news that the number of clinical trial recruiting sites in Ukraine has dropped by half since the Russian invasion, DDW’s Diana Spencer examines clinical trial data from analytics company Phesi and speaks to Dr Olena Karpenko , Clinical Research Director at Medical Center Ok!Clinic+ Ongoing clinical trials.

Clinical Research 52

Clinical Research Research Clinical Trials Clinical Trials 52

The Pharma Data

JUNE 28, 2021

The approval is based on the results of the pivotal Phase III VICTORIA trial, published in The New England Journal of Medicine (NEJM) in March 2020. Bayer is proud of the approval of vericiguat in Japan and the contribution it has shown in clinical trials.”. The vericiguat program is being co-developed by Bayer and MSD.

Cardiology 52

Cardiology Production Development Medicine 52

The Pharma Data

MARCH 31, 2023

Global Head, Cardiovascular, Renal and Metabolism Development Unit, Novartis. The positive opinion is based on final data from the 52-week Phase III PANORAMA-HF trial – the largest pediatric heart failure study ever conducted – and extrapolation of adult heart failure data from the Phase III PARADIGM-HF trial to pediatric patients 3,4.

Medicine 75

Medicine Trials Cardiology Production 75

Scienmag

NOVEMBER 13, 2020

Empagliflozin, a recently developed diabetes drug, can effectively treat and reverse heart failure in both diabetic and non-diabetic patients, according to researchers at the Icahn School of Medicine at Mount Sinai.

Clinical Trials 61

Clinical Trials Clinical Trials Drugs Medicine 61

The Pharma Data

FEBRUARY 21, 2022

At its annual Pharma Media Day 2022, Bayer presented the latest developments in the ongoing transformation of its pharmaceuticals business, which is aimed at delivering long-term, sustainable business growth by bringing forward new options for patients.

Radiology 52

Radiology Cardiology Development Production 52

pharmaphorum

OCTOBER 2, 2020

The five new NIHR National Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. The webinar will also cover: What the NPRCs’ franchise model means for research delivery.

Clinical Trials 92

Clinical Trials Clinical Trials Life Science Clinical Research 92

The Pharma Data

MARCH 13, 2022

(NYSE: PFE) announced today the completion of its acquisition of Arena Pharmaceuticals, a clinical stage company developing innovative potential therapies for the treatment of several immuno-inflammatory diseases. The root cause of many immunological diseases is immuno-inflammation, which requires specifically designed agents. .:

Dermatology 52

Dermatology Cardiology Development Medicine 52

Scienmag

MAY 16, 2021

A unique commission that today issued major new recommendations aimed at fully understanding and reducing the global burden of heart disease in women was led by Roxana Mehran, MD, Professor of Medicine, and Population Health Science and Policy, and Director of Interventional Cardiovascular Research and Clinical Trials at the Icahn School of Medicine (..)

Clinical Trials 50

Clinical Trials Clinical Trials Medicine Trials 50

pharmaphorum

JUNE 1, 2021

Novo Nordisk is paying $55 million upfront to secure rights to a cell therapy for heart failure developed by Japanese startup Heartseed. Working out which are more likely to benefit from stem cell therapy is likely to be a key challenge for developers. An interim look at the results is due later this month.

Trials 138

Trials Development Licensing Licensing 138

Scienmag

JUNE 17, 2021

Tools for clinicians in point-of-care use UTICA, NY — More than 2 million coronary artery stents are implanted each year to help protect or restore normal blood flow to the heart, to treat patients suffering from angina or a heart attack due to coronary artery disease (CAD). While stents are highly effective and safe devices, […].

Research 72

Research Development Clinical Trials Clinical Trials 72

pharmaphorum

OCTOBER 2, 2020

The five new NHS Patient Recruitment Centres (NPRCs) are set to shape the future of commercial clinical trials in the UK by offering new ways to conduct late-phase, large-scale research projects. The webinar will also cover: What the NPRCs’ franchise model means for research delivery.

Clinical Trials 52

Clinical Trials Clinical Trials Life Science Clinical Research 52

The Pharma Data

JULY 12, 2021

Bakris, MD, Department of Medicine, American Heart Association Comprehensive Hypertension Center, University of Chicago Medicine, USA and principal investigator of the FIDELIO-DKD trial. Up to 40% of all patients with type 2 diabetes develop chronic kidney disease. The study met its primary endpoint.

FDA Approval 52

FDA Approval Cardiology Medicine Trials 52

The Pharma Data

SEPTEMBER 5, 2021

Approval based on interim results from Phase III trial demonstrating complete terminal complement inhibition with reduced dosing frequency compared to Soliris. The approval follows the recommendation of the Committee for Medicinal Products for Human Use of the European Medicines Agency in July 2021.

Clinical Trials 52

Clinical Trials Clinical Trials Cardiology Trials 52

Scienmag

OCTOBER 6, 2020

Three ongoing influenza vaccine cardiovascular outcomes trials could hold insights into testing novel interventions against COVID-19 Seasonal influenza vaccine development and mass production, as well as three international influenza vaccine cardiovascular outcomes trials currently underway, may inform future efforts targeted at developing and evaluating (..)

Vaccination 40

Vaccination Vaccine Trials Production 40

The Pharma Data

DECEMBER 8, 2020

The company’s commercial priorities are three-fold: (1) Initially focusing its commercial efforts on rare diseases within its prolific neurology and cardiology franchises (2) pioneer new markets where there are no available treatments (3) create new standards of care where there has been a lack of innovation to optimize patient care.

Medicine 52

Medicine RNA Production Marketing 52

pharmaphorum

NOVEMBER 16, 2020

Dr Jan Westerink, assistant professor of internal medicine, University Medical Center, Utrecht, believes that one issue is that the guidelines for addressing cardiovascular risk are too rigid, and don’t take into account each patient’s individual circumstance. Jan Westerink studied medicine at Utrecht University (1997-2003).

Doctors 76

Doctors Doctor Cardiology Medicine 76

XTalks

NOVEMBER 19, 2021

Cardiac biomarkers can not only serve important roles in the diagnosis, management and prognosis of cardiac diseases, but they can also be significant tools in evaluating treatments in cardiovascular (CV) clinical trials. In CV clinical trials, cardiac biomarkers are most commonly included in efficacy and safety endpoints.

Clinical Trials 98

Clinical Trials Clinical Trials Trials In-Vitro 98

The Pharma Data

NOVEMBER 5, 2021

– In a new sub-analysis of the landmark EMPEROR-Preserved® phase III trial, Jardiance reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney function decline – Jardiance consistently improved outcomes across the full range of kidney function down to an eGFR of 20 mL/min/1.73

Trials 52

Trials Cardiology Drugs Development 52

Scienmag

JANUARY 11, 2021

COVID-19 pneumonia spreads like multiple wildfires, leaving destroyed lung tissue in its wake ‘This effort truly represents a “moonshot” in COVID-19 research’ Scientists identify target to treat COVID pneumonia and reduce severity Clinical trials with new experimental drug to begin early in 2021 Goal is to develop treatments (..)

Clinical Trials 49

Clinical Trials Clinical Trials Scientist Trials 49

The Pharma Data

SEPTEMBER 11, 2021

– Designation is based on results from the EMPEROR-Preserved phase III trial, which established Jardiance as the first therapy to show statistically significant improvement in heart failure outcomes in adults with heart failure with preserved ejection fraction. vice president, Product Development, Lilly.

Medicine 52

Medicine Insulin FDA Approval Trials 52

Rethinking Clinical Trials

APRIL 13, 2023

Nudges and other behavioral interventions are prevalent in industries like business and entertainment, but there is an opportunity for nudges in medicine and health care delivery. Launched in 2016, the Penn Medicine Nudge Unit is the world’s first behavioral design team embedded within a health system.

Medicine 100

Medicine Trials Cardiology Development 100

The Pharma Data

DECEMBER 15, 2020

And you won’t be spared simply by keeping high blood pressure at bay until you hit your golden years, because the study found that even those who hadn’t developed high blood pressure until becoming seniors still experienced a faster decline in thinking skills than those who continued to remain heart-healthy in their golden years.

Cardiology 52

Cardiology Clinical Trials Clinical Trials Medicine 52

The Pharma Data

AUGUST 29, 2020

Basel , August 30, 2020 — Novartis today announced results from a post-hoc analysis of pooled data from the Phase III ORION-10 and -11 trials evaluating the individual responses of patients on low-density lipoprotein cholesterol (LDL-C) reduction with inclisiran, a first-in-class investigational treatment for hyperlipidemia in adults.

Medicine 52

Medicine Containment Trials Production 52

The Pharma Data

NOVEMBER 4, 2020

Food and Drug Administration and European Medicine Agency as a potential therapy for patients with AL amyloidosis. Caelum”) is a clinical-stage biotechnology company developing treatments for rare and life-threatening diseases. CAEL-101 has received Orphan Drug Designation from both the U.S. About AL Amyloidosis.

Antibody 52

Antibody Containment Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 2, 2020

Bronchitol was developed by Pharmaxis Ltd., In three large-scale global clinical trials totaling 761 patients aged 18 years and older, Bronchitol use led to a sustained improvement in FEV 1 (Forced Expiratory Volume) versus control. It provides a compact, portable option to CF patients.

FDA Approval 52

FDA Approval Bacteria Medicine Cardiology 52

Pharma Marketing Network

JANUARY 12, 2023

Advancing medicine, advancing patient care, and advancing equity in our global workforce are shared values of this year’s honorees driving transformational change and impact,” said Wendy White, interim CEO and 2022 STAR, HBA. These experiences have empowered Christi to become a leading industry voice advocating fiercely for patients.

Life Science 52

Life Science Manufacturing Cardiology Development 52

The Pharma Data

AUGUST 30, 2021

The findings from the FIGARO-DKD study were presented today during a Hot Line session at ESC Congress 2021, and simultaneously published in the New England Journal of Medicine. Despite current treatment options, patients remain at high risk of progression to kidney failure and cardiovascular events,” said Professor Gerasimos Filippatos, M.D.,

HR 52

HR Cardiology Clinical Trials Clinical Trials 52